Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for C
April 16 2008 - 9:30AM
PR Newswire (US)
SNS-032 Demonstrates Activity in Multiple Myeloma and Mantle Cell
Lymphoma SOUTH SAN FRANCISCO, Calif., April 16
/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc.
(NASDAQ:SNSS) today reported data from nonclinical studies of
SNS-032 in multiple myeloma and mantle cell lymphoma. Data from
studies conducted in collaboration with the Multiple Myeloma
Research Consortium (MMRC) and with the University of Texas MD
Anderson Cancer Center were presented at the Annual Meeting of the
American Association for Cancer Research (AACR) in San Diego, CA.
SNS-032, a potent and selective inhibitor of cyclin-dependent
kinases (CDKs) 2, 7 and 9, is currently in a Phase 1 clinical trial
in patients with chronic lymphocytic leukemia (CLL) or multiple
myeloma. "Our collaborations with leading oncology thought leaders,
such as Dr. Trudel and the MMRC Validation Team and Dr. Plunkett of
MD Anderson Cancer Center, provide us with important new insights
into SNS-032's activity in hematologic cancers," said Daniel C.
Adelman, M.D., Senior Vice President, Development and Chief Medical
Officer of Sunesis. "Results presented today from studies in
primary and human cell lines demonstrate SNS-032's potential both
alone and in combination with other agents in multiple myeloma and
other B cell malignancies and further support our ongoing Phase 1
clinical trial." An oral presentation by Suzanne Trudel, MSc, M.D.,
Assistant Professor, Princess Margaret Hospital, University Health
Network in Toronto, Canada, focused on results from studies by the
MMRC Validation Team, in collaboration with Sunesis scientists, of
SNS-032 in human myeloma cell lines and primary multiple myeloma
cells. SNS-032 demonstrated broad, mechanism-based activity in the
human myeloma cell lines and preferentially induced apoptosis in
primary multiple myeloma cells versus peripheral blood mononuclear
cells. In a series of studies examining SNS-032's mechanism of
action and activity in human myeloma cell lines, SNS-032 inhibited
proliferation and induced apoptosis, down-regulating key
anti-apoptotic proteins and resulting in G1 arrest. In addition,
SNS-032 was active in combination with two approved agents for
multiple myeloma, bortezomib (Velcade(R)) and lenalidomide
(Revlimid(R)), in human myeloma cell lines. SNS-032 also
demonstrated anticancer activity in vivo in a transgenic mouse
model of multiple myeloma. These data (Abstract #4972) were
presented during a minisymposium on Novel Genomic Approaches,
Drugs, Targets, and Strategies in a talk titled "SNS-032, a potent
and selective CDK2, 7 and 9 inhibitor, demonstrates preclinical
activity in human multiple myeloma." In addition, on Sunday, April
13, 2008 at the AACR Annual Meeting, William Plunkett, Ph.D.,
Professor and Chief, Section of Molecular and Cellular Oncology at
the University of Texas MD Anderson Cancer Center, presented
translational research data detailing the relationship between
SNS-032's mechanism and its activity in mantle cell lymphoma.
Mantle cell lymphoma is an aggressive form of Non-Hodgkin's
lymphoma driven by the over-expression of certain oncoproteins,
including cyclin D1, Mcl-1 and Myc. SNS-032's targeted inhibition
of CDKs 7 and 9 blocks transcription of these proteins, resulting
in cell death in a panel of mantle cell lymphoma cell lines. These
data were presented at the AACR Annual Meeting in a poster titled
"SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7, and
9, blocks transcription of cyclin D1 and Mcl-1, causing cell death
in mantle cell lymphoma cell lines" (Abstract #756). About Sunesis
Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel small molecule therapeutics for oncology and other serious
diseases. Sunesis has built a broad product candidate portfolio
through internal discovery and in-licensing of novel cancer
therapeutics. Sunesis is advancing its product candidates through
in-house research and development efforts and strategic
collaborations with leading pharmaceutical and biopharmaceutical
companies. For additional information on Sunesis Pharmaceuticals,
please visit http://www.sunesis.com/. SUNESIS and the logo are
trademarks of Sunesis Pharmaceuticals, Inc. Other trademarks are
the property of their respective owners. Safe-Harbor Statement This
press release contains forward-looking statements including without
limitation statements related to the potential activity and uses of
SNS-032, and the potential for SNS-032 to be tested in other
indications. Words such as "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon Sunesis' current
expectations. Forward-looking statements involve risks and
uncertainties. Sunesis' actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risk that
Sunesis' drug discovery and development activities, including
enrollment and reporting of results, could be halted significantly
or delayed for various reasons, the risk that Sunesis' clinical
trials for SNS-032 may not demonstrate safety or efficacy or lead
to regulatory approval, the risk that preliminary data and trends
may not be predictive of future data or results, the risk that
Sunesis' preclinical studies and clinical trials may not satisfy
the requirements of the FDA or other regulatory agencies, risks
related to the conduct of Sunesis' clinical trials and
manufacturing of SNS-032 and risks related to Sunesis' need for
additional funding. These and other risk factors are discussed
under "Risk Factors" and elsewhere in Sunesis' annual report on
Form 10-K for the year ended December 31, 2007 and other filings
with the Securities and Exchange Commission. Sunesis expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in the company's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. DATASOURCE: Sunesis
Pharmaceuticals, Inc. CONTACT: Investors, Eric Bjerkholt, SVP,
Corp. Development & Finance of Sunesis Pharmaceuticals, Inc.,
+1-650-266-3717; or Media, Karen L. Bergman or Michelle Corral,
both of BCC Partners, +1-650-575-1509, or +1-415-794-8662, for
Sunesis Pharmaceuticals, Inc. Web site: http://www.sunesis.com/
Copyright
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024